I. Babic

发表

Multiple spatially related pharmacophores define small molecule inhibitors of OLIG2 in glioblastoma

S. Pastorino, I. Tsigelny, S. Kesari, 2015, Oncotarget.

SUMO modification of Sam68 enhances its ability to repress cyclin D1 expression and inhibits its ability to induce apoptosis

I. Babic, D. Fujita, E. Cherry, 2006, Oncogene.

CELL BIOLOGY AND SIGNALING

V. P. Collins, Michael A. Koldobskiy, R. Spang, 2010 .

Cellular immunotherapy of cancer: an overview and future directions.

S. Kesari, I. Babic, V. Yenugonda, 2017, Immunotherapy.

The Src Homology 2 (SH2) Domain of SH2-containing Inositol Phosphatase (SHIP) Is Essential for Tyrosine Phosphorylation of SHIP, Its Association with Shc, and Its Induction of Apoptosis*

I. Babic, M. Hughes, G. Krystal, 1997, The Journal of Biological Chemistry.

SHPS-1 Induces Aggregation of Ba/F3 Pro-B Cells Via an Interaction with CD471

I. Babic, F. Jirik, F. Lindberg, 2000, The Journal of Immunology.

Via an Interaction with CD 47 SHPS-1 Induces Aggregation of Ba / F 3 ProB

I. Babic, F. Jirik, F. Lindberg, 2000 .

Wnt pathway: a hallmark of drug discovery challenge.

S. Kesari, I. Babic, Elmar Nurmemmedov, 2018, Future medicinal chemistry.

A Binding Potency Assay for Pritumumab and Ecto-Domain Vimentin.

S. Kesari, I. Babic, M. Glassy, 2018, Methods in molecular biology.

MutS interaction with mismatch and alkylated base containing DNA molecules detected by optical biosensor.

I. Babic, F. Jirik, S. Andrew, 1996, Mutation research.

In vivo and in vitro mutagenesis of a Brassica napus acetolactate synthase gene for the production of herbicide resistance.

W. Crosby, M. Moloney, I. Babic, 1990 .

Pritumumab, the first therapeutic antibody for glioma patients.

S. Kesari, I. Babic, Elmar Nurmemmedov, 2017, Human antibodies.

Lyophilized brain tumor specimens can be used for histologic, nucleic acid, and protein analyses after 1 year of room temperature storage

Ivan Babic, Albert Lai, Donatello Telesca, 2013, Journal of Neuro-Oncology.

Mitochondrial p32 is upregulated in Myc expressing brain cancers and mediates glutamine addiction

S. Pastorino, Yoon-Jae Cho, S. Kesari, 2014, Oncotarget.

Allosteric inhibitor of β-catenin selectively targets oncogenic Wnt signaling in colon cancer

S. Kesari, R. Mukthavaram, I. Babic, 2020, Scientific Reports.

An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.

M. Prados, C. James, M. Mehta, 2011, Cancer discovery.

mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc.

Feng Liu, Ivan Babic, Paul S Mischel, 2013, Cell metabolism.

De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.

Ivan Babic, Paul S Mischel, Harley I Kornblum, 2013, Cancer discovery.

EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer.

Douglas L Black, Ivan Babic, Paul S Mischel, 2013, Cell metabolism.

A novel small molecule inhibitor of p32 mitochondrial protein overexpressed in glioma

I. Tsigelny, S. Kesari, V. Kouznetsova, 2017, Journal of Translational Medicine.

A Kinome-Wide RNAi Screen in Drosophila Glia Reveals That the RIO Kinases Mediate Cell Proliferation and Survival through TORC2-Akt Signaling in Glioblastoma

John B. Thomas, S. Vandenberg, P. Mischel, 2013, PLoS genetics.

An LXR agonist promotes GBM cell death through inhibition of an EGFR / AKT / SREBP-1 / LDLR-dependent pathway

M. Prados, C. James, M. Mehta, 2011 .

Discovery in context: leveraging multidimensional glioblastoma datasets to identify targetable regulatory networks.

Ivan Babic, Paul S Mischel, P. Mischel, 2012, Cancer discovery.

Multiple functions of a glioblastoma fusion oncogene.

P. Mischel, I. Babic, 2013, The Journal of clinical investigation.

Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.

Ivan Babic, Paul S Mischel, Timothy F Cloughesy, 2011, Cancer discovery.

Cellular target engagement: a new paradigm in drug discovery.

S. Kesari, I. Babic, Elmar Nurmemmedov, 2018, Future medicinal chemistry.

Invasive prostate carcinoma driven by c-Src and androgen receptor synergy.

Jiaoti Huang, O. Witte, I. Babic, 2011, Cancer research.

The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

C. James, J. Heath, T. Cloughesy, 2013, Clinical Cancer Research.

Cancer Therapy : Preclinical The mTOR Kinase Inhibitors , CC 2141 and CC 2142 , Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

C. James, J. Heath, T. Cloughesy, 2013 .

IRE1α and IGF signaling predict resistance to an endoplasmic reticulum stress-inducing drug in glioblastoma cells

H. Carter, S. Kesari, I. Babic, 2020, Scientific Reports.

A Role for Polypyrimidine Tract Binding Protein in the Establishment of Focal Adhesions

D. Black, I. Babic, Shalini Sharma, 2009, Molecular and Cellular Biology.

Antibody drug conjugates: Progress, pitfalls, and promises.

S. Kesari, I. Babic, Elmar Nurmemmedov, 2018, Human antibodies.

The RNA binding protein Sam68 is acetylated in tumor cell lines, and its acetylation correlates with enhanced RNA binding activity

I. Babic, D. Fujita, A. Jakymiw, 2004, Oncogene.

Cellular thermal shift analysis for interrogation of CRISPR-assisted proteomic changes.

S. Kesari, I. Babic, Elmar Nurmemmedov, 2020, BioTechniques.

[Autoimmune diseases of oral mucosa].

I. Babic, B. Marinovic, 2013, Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti.

Novel Pan-RAS Inhibitor ADT-007 Induces Tumor Regression in Mouse Models of GI Cancer

M. Boyd, G. Piazza, I. Babic, 2023, bioRxiv.